A bicarbonate-based purge solution for Impella® may be a viable alternative to heparin-based purge solution in patients who are heparin-intolerant and when heparin is contraindicated.
Claudius Mahr, DO, discusses outcome differences between patients with acute de novo cardiogenic shock and patients with chronic heart failure deteriorating to shock.
Adam Gottula, MD, discusses considerations for optimizing patient care when transporting patients supported with Impella or other mechanical circulatory support devices.
Chuck Simonton, MD, discusses the limitations of published papers that use administrative or payer databases as data sources and provides an AMI cardiogenic shock example.
Alexandra Lansky, MD, discusses a propensity-adjusted population-based analysis of Impella in patients undergoing high-risk PCI from a large-scale claims dataset.
